LI-cadherin Activators
LI-cadherin, also known as cadherin-13 (CDH13), is a calcium-dependent cell adhesion protein that plays a crucial role in mediating cell-cell interactions. While direct activators of LI-cadherin are not well-defined in the literature, several chemicals indirectly influence LI-cadherin expression through modulation of specific signaling pathways. Forskolin, a well-known adenylate cyclase activator, indirectly activates LI-cadherin by increasing intracellular cAMP levels. Elevated cAMP activates downstream signaling pathways, potentially impacting LI-cadherin expression and function. The TGF-β signaling pathway is another crucial player in LI-cadherin regulation. SB-431542, a selective TGF-β receptor kinase inhibitor, indirectly activates LI-cadherin by modulating this pathway. Inhibition of TGF-β receptor kinase alters downstream signaling events, influencing LI-cadherin expression. Additionally, A-769662, an AMP-activated protein kinase (AMPK) activator, indirectly activates LI-cadherin by promoting AMPK activity. Increased AMPK activity influences downstream signaling pathways that impact LI-cadherin expression.
Modulation of intracellular signaling cascades is further evident with LY-294002, a phosphoinositide 3-kinase (PI3K) inhibitor, influencing LI-cadherin expression through PI3K inhibition. XAV939, a tankyrase inhibitor, indirectly activates LI-cadherin by modulating the Wnt/β-catenin signaling pathway. Inhibition of tankyrase influences the stability of axin, leading to the activation of the Wnt pathway and subsequent modulation of LI-cadherin expression. Several other compounds, including GW9662, PD98059, CHIR-99021, H-89, Nsc-207895, and IQ-1, target different signaling pathways to indirectly influence LI-cadherin expression. These findings underscore the complexity of LI-cadherin regulation and the intricate interplay of various signaling pathways in controlling cadherin-mediated cell adhesion. Further research into the specific molecular mechanisms underlying these indirect activations will contribute to a comprehensive understanding of LI-cadherin function in cellular processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin, an adenylate cyclase activator, indirectly activates LI-cadherin by increasing intracellular cAMP levels. Elevated cAMP activates downstream signaling pathways that influence LI-cadherin expression and function. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542, a selective inhibitor of TGF-β receptor kinase, indirectly activates LI-cadherin by modulating the TGF-β signaling pathway. Inhibition of TGF-β receptor kinase alters downstream signaling events, influencing LI-cadherin expression. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A-769662, an AMP-activated protein kinase (AMPK) activator, indirectly activates LI-cadherin by promoting AMPK activity. Increased AMPK activity influences downstream signaling pathways that impact LI-cadherin expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY-294002, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly activates LI-cadherin by inhibiting PI3K activity. Modulation of the PI3K signaling pathway alters downstream events, influencing LI-cadherin expression. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW9662, a selective peroxisome proliferator-activated receptor gamma (PPARγ) antagonist, indirectly activates LI-cadherin by inhibiting PPARγ activity. Modulation of PPARγ alters downstream signaling events, influencing LI-cadherin expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a selective mitogen-activated protein kinase kinase (MEK) inhibitor, indirectly activates LI-cadherin by inhibiting the MEK/ERK signaling pathway. Inhibition of MEK alters downstream signaling events, influencing LI-cadherin expression. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
GSK-3 Inhibitor XVI (CHIR-99021), a glycogen synthase kinase-3 (GSK-3) inhibitor, indirectly activates LI-cadherin by modulating the Wnt/β-catenin signaling pathway. Inhibition of GSK-3 influences the stability of β-catenin, leading to the activation of the Wnt pathway and subsequent modulation of LI-cadherin expression. | ||||||
NSC-207895 | 58131-57-0 | sc-364550 sc-364550A | 5 mg 10 mg | $354.00 $666.00 | ||
NSC-207895, a vacuolar ATPase (V-ATPase) inhibitor, indirectly activates LI-cadherin by modulating intracellular pH. Inhibition of V-ATPase disrupts cellular pH homeostasis, influencing downstream signaling events that impact LI-cadherin expression. | ||||||
IQ-1 | 331001-62-8 | sc-202665 | 10 mg | $180.00 | 2 | |
IQ-1, a β-catenin stabilizer, indirectly activates LI-cadherin by promoting the stability of β-catenin. Increased β-catenin stability influences downstream signaling events that impact LI-cadherin expression. | ||||||